MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

Surmodics, Inc. SRDX demonstrated strong performance in the last reported quarter. Its loss per share was 51.9% narrower than the market estimate and sales beat the same by 8.3%. The strong ...

The US healthcare system under Trump 2.0 are likely to benefit Indian players, except for the push for increased US drug ...

Exelixis, Inc. (NASDAQ:EXEL), currently trading near $33, continues to build on the success of its flagship product ...

Inhibrx Biosciences , Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company valued at $205.41 million, is navigating a critical phase in its development as it advances its oncology pipeline.

Michael Benkowitz, President and COO of United Therapeutics Corp (NASDAQ:UTHR), recently executed a series of stock transactions involving the company's common stock. On January 21, Benkowitz sold ...

Shares were up 30% to 5.18 Canadian dollars Wednesday. Medexus will target a commercial launch in the first half of calendar 2025. The company believes product-level revenue in the U.S. has the ...

Trump's return to the White House has introduced significant uncertainty for investors in the medical device industry. Major ...

DALLAS - Spectral AI, Inc. (NASDAQ:MDAI), a Dallas-based company specializing in medical diagnostics with its AI-driven DeepView® System, has announced its expected financial outcomes for the year ...

This article is based on a press release statement from Rigel Pharmaceuticals (NASDAQ:RIGL), Inc. The company maintains a healthy financial position with a current ratio of 1.96 and operates with a ...

LONDON and NEW YORK - OKYO Pharma Limited (NASDAQ: OKYO), a $36.54 million market cap biotechnology company currently trading at $1.04 per share, engaged in the development of treatments for ocular ...